Article

You have free access to this content

Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

  1. Enriqe Z. Fisman M.D.1,*,
  2. Alexander Tenenbaum M.D., Ph.d.1,
  3. Yehuda Adler M.D.1,
  4. Michael Motro M.D.1,
  5. Valentina Boyko M.S.2,
  6. Michal Benderly M.S.2,
  7. Aharon Friedensohn M.D.2,
  8. Mira Kohanovski M.D.2,
  9. Rene Rotzak M.D.2,
  10. Hanan Schneider M.D.2,
  11. Solomon Behar M.D.2

Article first published online: 7 AUG 2009

DOI: 10.1002/clc.4960240210

Issue

Clinical Cardiology

Clinical Cardiology

Volume 24, Issue 2, pages 151–158, February 2001

Additional Information

How to Cite

Fisman, E. Z., Tenenbaum, A., Adler, Y., Motro, M., Boyko, V., Benderly, M., Friedensohn, A., Kohanovski, M., Rotzak, R., Schneider, H. and Behar, S. (2001), Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol, 24: 151–158. doi: 10.1002/clc.4960240210

Author Information

  1. 1

    Cardiac Rehabilitation Institute

  2. 2

    the Bezafibrate Infarction Prevention Coordinating Center, Neufeld Cardiac Research Institute, the Chaim Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

*Cardiac Rehabilitation Institute Chaim Sheba Medical Center 52621 Tel-Hashomer, Israel

Publication History

  1. Issue published online: 7 AUG 2009
  2. Article first published online: 7 AUG 2009
  3. Manuscript Accepted: 12 MAY 2000
  4. Manuscript Received: 11 JAN 2000

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (838K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Edelmiro Menéndez Torre, Francisco Javier Lafita Tejedor, Sara Artola Menéndez, Jesús Millán Núñez-Cortés, Ángeles Alonso García, Manuel Puig Domingo, José Ramón García Solans, Fernando Álvarez Guisasola, Javier García Alegría, Javier Mediavilla Bravo, Carlos Miranda Fernández-Santos, Ramón Romero González, Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2, Clínica e Investigación en Arteriosclerosis, 2011, 23, 1, 40

    CrossRef

  2. You have free access to this content2
    Laurent Azoulay, Verena Schneider-Lindner, Sophie Dell'Aniello, Alicia Schiffrin, Samy Suissa, Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study, Pharmacoepidemiology and Drug Safety, 2010, 19, 4
    Direct Link:
  3. 3
    Giovanni Corrao, Silvana Antonietta Romio, Antonella Zambon, Luca Merlino, Emanuele Bosi, Marina Scavini, Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy, European Journal of Clinical Pharmacology, 2010, 67, 3, 289

    CrossRef

  4. 4
    B. Sillars, W. A. Davis, I. B. Hirsch, T. M. E. Davis, Sulphonylurea–metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study, Diabetes, Obesity and Metabolism, 2010, 12, 9
    Direct Link:
  5. 5
    Matteo Anselmino, Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents, Journal of Diabetes and its Complications, 2009, 23, 6, 427

    CrossRef

  6. 6
    ELVIRA O. GOSMANOVA, ROBERT B. CANADA, THERESE A. MANGOLD, WILLIAM N. RAWLS, BARRY M. WALL, Effect of Metformin-Containing Antidiabetic Regimens on All-cause Mortality in Veterans With Type 2 Diabetes Mellitus, The American Journal of the Medical Sciences, 2008, 336, 3, 241

    CrossRef

  7. 7
    R. E. Buckingham, A. Hanna, Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?, Diabetes, Obesity and Metabolism, 2008, 10, 4
    Direct Link:
  8. 8
    H. T. Horsdal, S. P. Johnsen, F. Søndergaard, J. Rungby, Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study, Diabetologia, 2008, 51, 4, 567

    CrossRef

  9. 9
    M. Monami, D. Balzi, C. Lamanna, A. Barchielli, G. Masotti, E. Buiatti, N. Marchionni, E. Mannucci, Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality, Diabetes/Metabolism Research and Reviews, 2007, 23, 6
    Direct Link:
  10. 10
    Odd Erik Johansen, KÃ¥re I Birkeland, Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus, American Journal of Cardiovascular Drugs, 2007, 7, 5, 319

    CrossRef

  11. 11
    J. A. Tayek, Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936, Diabetologia, 2006, 49, 11, 2807

    CrossRef

  12. 12
    &NA;, Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant, Drugs & Therapy Perspectives, 2006, 22, 4, 18

    CrossRef

  13. 13
    J. M. M. Evans, S. A. Ogston, A. Emslie-Smith, A. D. Morris, Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin, Diabetologia, 2006, 49, 5, 930

    CrossRef

  14. 14
    Matteo Monami, Chiara Luzzi, Caterina Lamanna, Veronica Chiasserini, Filomena Addante, Carla Maria Desideri, Giulio Masotti, Niccolò Marchionni, Edoardo Mannucci, Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin, Diabetes/Metabolism Research and Reviews, 2006, 22, 6
    Direct Link:
  15. 15
    J. A. Johnson, S. H. Simpson, E. L. Toth, S. R. Majumdar, Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes, Diabetic Medicine, 2005, 22, 4
    Direct Link:
  16. 16
    George E Dailey, Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes, Expert Opinion on Pharmacotherapy, 2003, 4, 8, 1417

    CrossRef

  17. 17
    L. S. Hermann, G. Lindberg, U. Lindblad, A. Melander, Efficacy, effectiveness and safety of sulphonylurea–metformin combination therapy in patients with type 2 diabetes, Diabetes, Obesity and Metabolism, 2002, 4, 5
    Direct Link:
  18. 18
    Antonio Saenz, Inmaculada Fernandez-Esteban, Angel Mataix, Monica Ausejo Segura, Marta Roqué i Figuls, David Moher, Metformin monotherapy for type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
  19. 19
    Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
  20. 20
    Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter (posthumous), Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
  21. 21
    S Salpeter, E Greyber, G Pasternak, E Salpeter, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
  22. 22
    Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
    Direct Link:
Get PDF (838K)